{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:27:23Z","timestamp":1790623643188,"version":"4.1.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Imatinib has changed the treatment of chronic myeloid leukemia (CML) drastically since 15 years. It is usually well tolerated, but severe persistent marrow aplasia is an unusual complication of imatinib while using it in CML. The aim of this study is to describe our experience confronting this rare side effect and review the available data worldwide.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>It was a retrospective analysis conducted at a center from February 2002 to February 2015. This study was endorsed by our Institutional Review Board (IRB) and written consent was taken from all patients. Patients diagnosed as Philadelphia (Ph) chromosome-positive CML either in chronic phase (CP), accelerated phase (AP), or blastic crisis (BC) were included. There were a total of 1,576 patients with CML treated with imatinib during this period. Karyotyping and quantitative reverse transcriptase polymerase chain reaction (RT-qPCR) were done at the time of pancytopenia for all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In total, 11 (males = 5, females = 6) patients met our inclusion criteria from 1,576 patients of CML. The median age was 58 years (range 32\u201376). Out of 11 patients 8, 2, and 1 patients were in CP, AP, and BC phases, respectively. The median time of administration of imatinib was 3.3 months (range 1.5\u20136). The average time of marrow recovery was 10.4 months (range 5\u201315). Two patients expired (one from septicemia and the other from intracranial hemorrhage). BCR-ABL transcripts level by RT-PCR revealed the existence of the disease in all patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Imatinib is a very well-tolerated tyrosine kinase inhibitor (TKI), but is associated with persistent myelosuppression when used in older age, advanced phase of the disease, and treated previously. After confirming persistent marrow aplasia, the treatment is mainly supportive. It is striking that the disease is still persistent, which is confirmed by RT-PCR. There is no consensus regarding recalling imatinib at lower doses or the use of second-generation TKI (nilotinib, dasatinib) in these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_1594_20","type":"journal-article","created":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T01:12:07Z","timestamp":1686618727000},"page":"335-339","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Severe persistent marrow aplasia in chronic myeloid leukemia (CML): An unusual complication of imatinib"],"prefix":"10.4103","volume":"19","author":[{"given":"Irappa","family":"Madabhavi","sequence":"first","affiliation":[{"name":"Department of Medical and Pediatric Oncology, Kerudi Cancer Hospital, Bagalkot, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apurva","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Anand","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Panchal","sequence":"additional","affiliation":[{"name":"Department of Medical and Pediatric Oncology, GCRI, Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"R1-20241021","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2165\/00003495-200161120-00007","article-title":"Imatinib","volume":"61","author":"Lyseng-Williams","year":"2001","journal-title":"Drugs"},{"key":"R2-20241021","first-page":"4861673","article-title":"Aplasia in chronic phase CML post-TKI therapy:A management dilemma","volume":"2019","author":"Ramdial","year":"2019","journal-title":"Case Rep Hematol"},{"key":"R3-20241021","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ajh.20776","article-title":"Bone marrow aplasia\u2014Arare complication of imatinib therapy in CML patients","volume":"82","author":"Srinivas","year":"2007","journal-title":"Am J Hematol"},{"key":"R4-20241021","first-page":"868","article-title":"Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinibmesylate therapy","volume":"43","author":"Sumi","year":"2002","journal-title":"Rinsho Ketsueki"},{"key":"R5-20241021","first-page":"332","article-title":"Imatinibmesylate induced severe bone marrow aplasia in a patient with long duration of chronic myelogenous leukemia treated previously with busulphan and hydroxyurea","volume":"6","author":"Robak","year":"2005","journal-title":"Case Rep Clin Pract Rev"},{"key":"R6-20241021","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"R7-20241021","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"R8-20241021","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.leukres.2007.03.016","article-title":"Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia","volume":"32","author":"Cervetti","year":"2008","journal-title":"Leukemia Res"},{"key":"R9-20241021","first-page":"95a","article-title":"High rates of major cytogenetic response in patients with newly diagnosed chronic myeloid leukemia (CML) in early chronic phase treated with imatinib at 400 mg or 800 mg daily [abstract","volume":"100","author":"Cortes","year":"2002","journal-title":"Blood"},{"key":"R10-20241021","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinibmesylate in advanced gastrointesinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N Engl J Med"},{"key":"R11-20241021","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/blood-2003-05-1535","article-title":"Inhibitory effect of imatinib on normal progenitor cells in vitro","volume":"103","author":"Bartolovic","year":"2004","journal-title":"Blood"},{"key":"R12-20241021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2184.2007.00438.x","article-title":"Inhibition of platelet-derived growth factor receptorbeta by imatinibmesylate suppresses proliferation and alters differentiation of human mesenchymal stem cells in vitro","volume":"40","author":"Fierro","year":"2007","journal-title":"Cell Prolif"},{"key":"R13-20241021","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1196\/annals.1349.022","article-title":"Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells","volume":"1044","author":"Balabanov","year":"2005","journal-title":"Ann N Y Acad Sci"},{"key":"R14-20241021","first-page":"136","article-title":"Relationship between cytopenia and cytogenetic response in imatinibmesylate treated Ph-positive chronic myeloid leukemia in chronic phase patients","volume":"35","author":"Jiang","year":"2003","journal-title":"Beijing Da Xue Xue Bao"},{"key":"R15-20241021","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/cncr.11863","article-title":"The significance of myelosuppression during therapy with imatinibmesylate in patients with chronic myelogenous leukemia in chronic phase","volume":"100","author":"Sneed","year":"2004","journal-title":"Cancer"},{"key":"R16-20241021","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/bloodadvances.2018027516","article-title":"Bone marrow fibrosis associated with long-term imatinib therapy:Resolution after switching to a second-generation TKI","volume":"3","author":"Shanmuganathan","year":"2019","journal-title":"Blood Adv"},{"key":"R17-20241021","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/PAT.0b013e32834e42df","article-title":"Bone marrow with gelatinous transformation associated with residual disease inimatinibmesylate-treated chronicmyelogenous leukaemia (CML)","volume":"44","author":"Thakral","year":"2012","journal-title":"Pathology"},{"key":"R18-20241021","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000121825","article-title":"Gelatinous transformation of bone marrow in chronic myeloid leukemia during treatment with imatinibmesylate:A disease or a drug effect?","volume":"119","author":"Ram","year":"2008","journal-title":"Acta Haematol"},{"key":"R19-20241021","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s12288-012-0188-1","article-title":"Gelatinous marrow transformation in an imatinib-treated CML patient with pancytopenia following severe sepsis","volume":"30","author":"Agrawal","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R20-20241021","doi-asserted-by":"crossref","first-page":"627","DOI":"10.18203\/2320-6012.ijrms20190371","article-title":"Imatinib induced bone marrow hypoplasia in a case of chronic myelogenous leukemia","volume":"7","author":"Kausar","year":"2019","journal-title":"Int J Res Med Sci"},{"key":"R21-20241021","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF02982603","article-title":"Recovery of normal hematopoiesis after severe bone marrow aplasia induced by interferon-alpha in a patient with chronic myelogenous leukemia","volume":"77","author":"Hishida","year":"2003","journal-title":"Int J Hematol"},{"key":"R22-20241021","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1600-0609.2009.01269.x","article-title":"Nilotinib-induced bone marrow aplasia","volume":"83","author":"Song","year":"2009","journal-title":"Eur J Haematol"},{"key":"R23-20241021","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia (ENESTndstudy)","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"key":"R24-20241021","first-page":"539","article-title":"Successful induction of complete cytogenetic response with low-doseimatinibmesylate in an accelerated phase chronic myelogenous leukemia patient who developed severe bone marrow aplasia following standard-doseimatinibmesylate therapy","volume":"37","author":"Nakazato","year":"2010","journal-title":"Gan To Kagaku Ryoho"},{"key":"R25-20241021","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.leukres.2004.11.017","article-title":"Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia","volume":"29","author":"Chng","year":"2005","journal-title":"Leuk Res"},{"key":"R26-20241021","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1080\/10428190500046778","article-title":"Severe bone marrow aplasia followingimatinibmesylate in a patient with chronic myelogenousleukemia","volume":"46","author":"Lokeshwar","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"R27-20241021","first-page":"176","article-title":"Imatinib related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia","volume":"18","author":"Khan","year":"2008","journal-title":"J Coll Physicians Surg Pak"},{"key":"R28-20241021","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1177\/1078155212438112","article-title":"Recurrentbone marrowaplasiasecondary tonilotinibin a patient with chronic myeloid leukemia:A case report","volume":"18","author":"Prodduturi","year":"2012","journal-title":"J Oncol Pharm Pract"},{"key":"R29-20241021","doi-asserted-by":"crossref","first-page":"811","DOI":"10.3109\/10428194.2014.935367","article-title":"Spontaneous recovery of severenilotinib-inducedbone marrowaplasia and successful retreatment with dasatinib in a patient with Chronic Phase Chronic Myeloid Leukemia","volume":"56","author":"Estephan","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R30-20241021","first-page":"139a","article-title":"Myeloid growth factors for neutropenia during imatinibmesylate (STI 571) therapy for CML:Preliminary evidence of safety and efficacy","volume":"98","author":"Mauro","year":"2001","journal-title":"Blood"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1594_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:33Z","timestamp":1787067513000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_1594_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_1594_20","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"2020-12-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}